Table 3.

Determinants of the graft transplant outcome at the time of biopsy (univariate and multivariate Cox proportional hazards model)

CharacteristicCrude HR (95% CI)P ValueAdjusted HR (95% CI)P Value
Recipient age per increase of 1 yr0.97 (0.94 to 0.99)0.021 (0.96 to 1.03)0.99
Time interval after transplantation per increase of 1 yr1.09 (1.04 to 1.13)<0.0011.15 (1.04 to 1.27)<0.01
i+t≥2 Versus <22.54 (1.06 to 5.71)0.032.07 (0.76 to 5.17)0.14
g+cpt≥2 Versus <21.24 (0.56 to 2.80)0.60Not includedNot included
ci+ct≥2 Versus <22.15 (0.74 to 9.16)0.17Not includedNot included
DSA at biopsy, yes versus no2.2 (0.93 to 5.79)0.062.05 (0.78 to 5.74)0.14
Plasma creatinine at biopsy ≥180 versus <180 μmol/La3.89 (1.56 to 11.73)0.0023.72 (1.29 to 13.72)0.01
Urine protein-to-creatinine ratio at biopsy ≥0.1 versus <0.1 g/mmolb4.10 (1.84 to 9.57)<0.0011.96 (0.76 to 5.25)0.16
uANG at biopsyc
 ≥5.48 versus<5.48 ng/mmol4.11 (1.65 to 12.4)0.0023.59 (1.12 to 15.94)0.02
 Per unit increment2 (1.37 to 2.88)<0.0012.53 (1.5 to 4.28)<0.001
  • Adjusted HRs were calculated with the use of a multivariate model incorporating all covariates listed in the table that were associated (P<0.10) with graft loss in the univariate analysis. DSA, donor-specific antibody.

  • a Plasma creatinine at biopsy ≥180 versus <180 μmol/L corresponds to the median of the distribution of the creatinine values in the cohort.

  • b Urine protein-to-creatinine ratio at biopsy ≥0.1 versus <0.1 g/mmol, which corresponds to approximately 1 g/24 h, a validated cutoff for diagnosis, prognosis, and management of proteinuria.

  • c uANG at biopsy ≥5.48 versus <5.48 ng/mmol corresponds to the median of the distribution of the uANG values in the cohort. uANG refers to Ln(uANG/creatinine).